Regeneron Pharmaceuticals (REGN) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Regeneron Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$13.12B

Latest Revenue (Q)

$3.72B

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Regeneron Pharmaceuticals Revenue by Period

Regeneron Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	$13.12B	7.76%
2022-12-31	$12.17B	-24.26%
2021-12-31	$16.07B	89.14%
2020-12-31	$8.50B	8.06%
2019-12-31	$7.86B	17.18%
2018-12-31	$6.71B	14.28%
2017-12-31	$5.87B	20.82%
2016-12-31	$4.86B	18.44%
2015-12-31	$4.10B	45.55%
2014-12-31	$2.82B	33.96%
2013-12-31	$2.10B	52.69%
2012-12-31	$1.38B	209.20%
2011-12-31	$445.82M	-2.89%
2010-12-31	$459.07M	21.04%
2009-12-31	$379.27M	59.05%
2008-12-31	$238.46M	90.73%
2007-12-31	$125.02M	97.05%
2006-12-31	$63.45M	-4.15%
2005-12-31	$66.19M	-61.96%
2004-12-31	$174.02M	202.65%
2003-12-31	$57.50M	161.49%
2002-12-31	$21.99M	0.07%
2001-12-31	$21.97M	-62.93%
2000-12-31	$59.28M	71.81%
1999-12-31	$34.50M	-9.69%
1998-12-31	$38.20M	15.41%
1997-12-31	$33.10M	37.34%
1996-12-31	$24.10M	-12.04%
1995-12-31	$27.40M	18.10%
1994-12-31	$23.20M	118.87%
1993-12-31	$10.60M	-

Regeneron Pharmaceuticals generated $13.12B in revenue during NA 2023, up 7.76% compared to the previous quarter, and up 195.46% compared to the same period a year ago.

Regeneron Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	$3.72B	4.89%
2024-06-30	$3.55B	12.79%
2024-03-31	$3.15B	-8.42%
2023-12-31	$3.43B	2.13%
2023-09-30	$3.36B	6.48%
2023-06-30	$3.16B	-0.13%
2023-03-31	$3.16B	-7.39%
2022-12-31	$3.41B	16.29%
2022-09-30	$2.94B	2.76%
2022-06-30	$2.86B	-3.64%
2022-03-31	$2.97B	-40.12%
2021-12-31	$4.95B	43.41%
2021-09-30	$3.45B	-32.81%
2021-06-30	$5.14B	103.21%
2021-03-31	$2.53B	4.37%
2020-12-31	$2.42B	5.62%
2020-09-30	$2.29B	17.52%
2020-06-30	$1.95B	6.77%
2020-03-31	$1.83B	-15.73%
2019-12-31	$2.17B	5.91%
2019-09-30	$2.05B	5.93%
2019-06-30	$1.93B	12.96%
2019-03-31	$1.71B	-11.20%
2018-12-31	$1.93B	15.89%
2018-09-30	$1.66B	3.45%
2018-06-30	$1.61B	6.39%
2018-03-31	$1.51B	-4.48%
2017-12-31	$1.58B	5.45%
2017-09-30	$1.50B	2.08%
2017-06-30	$1.47B	11.46%
2017-03-31	$1.32B	7.51%
2016-12-31	$1.23B	0.55%
2016-09-30	$1.22B	0.62%
2016-06-30	$1.21B	0.98%
2016-03-31	$1.20B	9.36%
2015-12-31	$1.10B	-3.46%
2015-09-30	$1.14B	13.90%
2015-06-30	$998.62M	14.83%
2015-03-31	$869.61M	8.39%
2014-12-31	$802.33M	10.55%
2014-09-30	$725.79M	9.03%
2014-06-30	$665.70M	6.39%
2014-03-31	$625.74M	2.51%
2013-12-31	$610.41M	2.24%
2013-09-30	$597.03M	30.46%
2013-06-30	$457.64M	4.09%
2013-03-31	$439.66M	6.04%
2012-12-31	$414.60M	-3.06%
2012-09-30	$427.69M	40.50%
2012-06-30	$304.40M	31.33%
2012-03-31	$231.79M	88.48%
2011-12-31	$122.98M	19.59%
2011-09-30	$102.83M	-4.62%
2011-06-30	$107.81M	-3.92%
2011-03-31	$112.20M	-16.06%
2010-12-31	$133.68M	26.13%
2010-09-30	$105.98M	-8.55%
2010-06-30	$115.89M	11.93%
2010-03-31	$103.53M	6.96%
2009-12-31	$96.80M	-17.59%
2009-09-30	$117.45M	30.46%
2009-06-30	$90.03M	20.07%
2009-03-31	$74.98M	34.29%
2008-12-31	$55.84M	-14.86%
2008-09-30	$65.58M	8.13%
2008-06-30	$60.65M	7.57%
2008-03-31	$56.38M	-

Regeneron Pharmaceuticals generated $3.72B in revenue during Q3 2024, up 4.89% compared to the previous quarter, and up 117.81% compared to the same period a year ago.

Regeneron Pharmaceuticals Revenue Breakdown

Regeneron Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21
Collaboration Revenue	$5.50B	$2.06B	-
Product and Service, Other	$536.10M	$365.10M	$281.20M
Product	$7.08B	$6.89B	$12.12B

Regeneron Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (53.96%), Collaboration Revenue (41.95%), and Product and Service, Other (4.09%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Mar 18
Product	$1.95B	$1.92B	$1.76B	$1.85B	$1.79B	$1.77B	$1.67B	$1.70B	$1.80B	$1.75B	$1.64B	$3.98B	$2.28B	$4.14B	$1.72B	-
Collaboration Revenue	$1.66B	$1.52B	$1.27B	$1.37B	$1.44B	$1.32B	$1.38B	$-1.27B	$1.05B	$1.04B	$1.23B	$1.07B	$954.70M	$754.40M	-	-
Product and Service, Other	$114.20M	$104.50M	$116.90M	$212.50M	$138.30M	$69.30M	$116.00M	$127.70M	$84.20M	$59.20M	$94.00M	$86.20M	$99.00M	$46.00M	$50.00M	-
Antibody Collaboration	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$88.27M
Immuno-oncology Agreement	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.66B

Regeneron Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (52.31%), Collaboration Revenue (44.62%), and Product and Service, Other (3.07%).

Regeneron Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
UNITED STATES	$5.89B	$130.00M	$5.83B	$185.70M	$4.83B
Non-US	$324.30M	-	-	-	-
Rest Of World	-	$73.00M	-	-	-

Regeneron Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (94.78%), and Non-US (5.22%).

Quarterly Revenue by Country

Country	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
UNITED STATES	$1.54B	$1.53B	$1.40B	$1.50B	$1.45B	$40.50M	$40.20M	$35.50M	$29.70M	$31.20M	$33.60M	$2.30B	$676.70M	$2.59B	$262.20M	$1.62B	$40.20M	$1.23B	$1.24B	$1.29B
Rest Of World	$94.10M	$115.00M	$104.70M	$89.00M	$88.30M	$79.80M	$67.20M	$42.00M	$31.00M	-	-	-	-	-	-	-	-	-	-	-

Regeneron Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (94.23%), and Rest Of World (5.77%).

Regeneron Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
NVO	Novo Nordisk	$232.26B	$65.35B
REGN	Regeneron Pharmaceuticals	$13.12B	$3.72B
INCY	Incyte	$3.70B	$962.99M
BGNE	BeiGene	$2.46B	$929.17M
BMRN	BioMarin Pharmaceutical	$2.42B	$733.87B
UTHR	United Therapeutics	$2.33B	$748.90M
ALNY	Alnylam Pharmaceuticals	$1.83B	$420.15M
SRPT	Sarepta Therapeutics	$1.24B	$362.93M
PTCT	PTC Therapeutics	$937.82M	$135.42M
IONS	Ionis Pharmaceuticals	$787.65M	$225.25M
RARE	Ultragenyx Pharmaceutical	$434.25M	$147.03M
CRSP	CRISPR Therapeutics	$370.00M	$602.00K
APLS	Apellis Pharmaceuticals	$366.28M	$176.57M
ARWR	Arrowhead Pharmaceuticals	$240.74M	-
KRYS	Krystal Biotech	$50.70M	$83.84M
NTLA	Intellia Therapeutics	$36.27M	$9.11M
RXDX	Prometheus Biosciences	$6.81M	$1.10M
MDGL	Madrigal Pharmaceuticals	-	$62.17M

REGN Revenue FAQ

What is Regeneron Pharmaceuticals’s yearly revenue?

Regeneron Pharmaceuticals's yearly revenue for 2023 was $13.12B, representing an increase of 7.76% compared to 2022. The company's yearly revenue for 2022 was $12.17B, representing a decrease of -24.26% compared to 2021. REGN's yearly revenue for 2021 was $16.07B, representing an increase of 89.14% compared to 2020.

What is Regeneron Pharmaceuticals’s quarterly revenue?

Regeneron Pharmaceuticals's quarterly revenue for Q3 2024 was $3.72B, a 4.89% increase from the previous quarter (Q2 2024), and a 10.65% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $3.55B, a 12.79% increase from the previous quarter (Q1 2024), and a 12.32% increase year-over-year (Q2 2023). REGN's quarterly revenue for Q1 2024 was $3.14B, a -8.42% decrease from the previous quarter (Q4 2023), and a -0.54% decrease year-over-year (Q1 2023).

What is Regeneron Pharmaceuticals’s revenue growth rate?

Regeneron Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -18.38%, and for the last 5 years (2019-2023) was 66.81%.

What are Regeneron Pharmaceuticals’s revenue streams?

Regeneron Pharmaceuticals's revenue streams in c 23 are Collaboration Revenue, Product and Service, Other, and Product. Collaboration Revenue generated $5.5B in revenue, accounting 41.95% of the company's total revenue, up 167.35% year-over-year. Product and Service, Other generated $536.1M in revenue, accounting 4.09% of the company's total revenue, up 46.84% year-over-year. Product generated $7.08B in revenue, accounting 53.96% of the company's total revenue, up 2.67% year-over-year.

What is Regeneron Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Regeneron Pharmaceuticals was Product. This segment made a revenue of $7.08B, representing 53.96% of the company's total revenue.